You are here
The safer management of controlled drugs
We are responsible for making sure that health and social care providers, and other regulators, maintain a safe environment for managing controlled drugs in England.
In this update for 2018, we report on:
- the increase in opioid prescribing across the UK
- measures put in place following the Gosport Independent Panel report
- our continuing concerns regarding lower schedule controlled drugs
- the introduction of legislation for cannabis based medicinal products.
Our update shares the key issues raised by NHS England controlled drug accountable officers and their unaccounted-for losses of controlled drugs by NHS England area. We also give examples of issues raised and followed up through the local area networks.
As in previous years, we provide data on overall prescribing trends for controlled drugs in 2018, which were broadly similar to 2017. For 2018 we show the prescribing picture for opioids in Schedules 2 to 5 prescribed in combination with benzodiazepines, pregabalin or gabapentin across CCG areas of England, based on primary care prescription data.
There is a separate report on activity in 2018 from member organisations in the Controlled Drugs National Group and Cross-Border Group.
Previous safer management of controlled drugs reports
The safer management of controlled drugs 2017
The safer management of controlled drugs 2016
The safer management of controlled drugs 2015
The safer management of controlled drugs 2014
You can find our earlier reports on the safer management of controlled drugs on the National Archives.
- Last updated:
- 09 July 2019